mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say
The vaccine reportedly thwarted the cancer's return and spread.
Moderna and Merck disclosed on Wednesday that their innovative mRNA-based vaccine, personalized to target individual patients' cancer mutations, demonstrated efficacy in a Phase 3 melanoma clinical trial. While the announcement lacked specifics, the outcome could signify a significant breakthrough for both mRNA vaccines and tailored cancer treatments, demonstrating the first success for both treatment modalities.
The Phase 3 trial involved 1,137 patients with stage IIB–IV melanoma, which had been surgically removed before the trial commenced. Participants were randomly assigned a 2:1 ratio to receive either the customized mRNA vaccine (intismeran or mRNA-4157) combined with Merck's existing monoclonal antibody treatment Keytruda, or treatment with Keytruda alone.
Both groups underwent treatment for approximately a year. The trial was both placebo-controlled and double-blind, ensuring neither the doctors nor the patients were aware of the treatment allocation.
Written by urgent.news from Ars Technica Health's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Merck, Moderna claim 'promising' skin cancer vaccine results in key trial medicalxpress.com
- mRNA cancer vaccine succeeded in Phase 3 melanoma trial, Moderna and Merck say arstechnica.com
- Merck, Moderna claim 'promising' skin cancer vaccine results in key trial iol.co.za
- Merck, Moderna claim ‘promising’ skin cancer vaccine results in key trial torontosun.com
- Moderna shares double as cancer vaccine data rekindles investor hopes investing.com
- Moderna shares double as cancer vaccine data rekindles investor hopes finance.yahoo.com
